Exercise could work as treatment for prostate cancer

January 6, 2016
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.

The PANTERA study, led by Sheffield Hallam University, will focus on 50 men who have the disease, but whose cancer has not spread.Half of the men in the study will carry out two-and-a-half hours of aerobic exercise every week for 12 months - initially with the support of a qualified trainer and then with free access to local gyms. The other half will be given information about the benefits of exercise for cancer patients but will have no supervised sessions.

Prostate cancer that has not spread is sometimes treated with surgery or radiotherapy. But this can have side-effects so many men opt for active surveillance instead, which involves monitoring the disease. All the men in the PANTERA study are and will remain on active surveillance - and they will also be closely monitored as part of the study itself.

If the participants can successfully keep up their exercise regime for 12 months, the study is expected to lead to a full-scale trial to look at the potential benefits of combining active surveillance and exercise for some patients.

This trial - believed to be the first of its kind in the world - would aim to test whether can help keep prostate cancer from spreading to other parts of the body and could be a viable NHS treatment.

Study leader Dr Liam Bourke, principal research fellow at Sheffield Hallam University, said: "Evidence suggests that men who are physically active after a prostate cancer diagnosis have better cancer survival than men who aren't active. It's not clear yet how this works, but it might be that exercise affects the way some genes regulate cancer cell growth and DNA repair.

"The clinical academic team in Sheffield have been working hard for eight years to develop the intervention that is being tested in this exciting study. It builds on what we already know and is the first step towards finding out whether exercise could be an effective and practical NHS treatment for localised prostate cancer. If we show it works and is feasible, it could be a real leap forward and good news for cancer patients."

David Curtis (68) from Sheffield was diagnosed with early prostate cancer in March 2014 and has been exercising as part of the PANTERA study for several weeks - and continuing to exercise is one of his New Year resolutions. He said: "I was never someone to go to the gym, even though I've always been active, but now I go to the gym twice a week and do lots of walking. Since starting on the study, I've started to lose weight and my PSA level has come down which is a really positive indicator.

"I feel privileged to be on the study and pleased to be part of any research which might be useful to others."

PSA is produced by both normal and cancerous prostate cells, and a high PSA level in the blood can be a sign of cancer. Study researchers will check what effect regular exercise has on the body, including on PSA levels, and will also gather information about how well the study runs, to prepare for a full-scale trial.

In the UK, prostate cancer is the most common cancer in men with around 43,400 new cases diagnosed each year and around 10,800 deaths. Many types of prostate cancer grow extremely slowly and are not likely to spread, while others are more aggressive.

Professor Malcolm Mason, Cancer Research UK's prostate cancer expert, said: "Taking exercise is good for all of us, whether or not we have cancer - but this interesting study could help discover whether it's particularly helpful and a viable, additional treatment for some prostate cancer patients. Focusing on patients whose disease is under , rather than being treated in other ways, provides a fantastic opportunity to monitor the effects of on prostate cancer - and could even shed light on its potential as a supplemental therapy for other types of cancer."

Anyone interested in taking part in the study or finding out more about it, should visit cancerresearchuk.org/pantera.

Explore further: Men who forgo aggressive treatment for prostate cancer don't receive appropriate monitoring

Related Stories

Men who forgo aggressive treatment for prostate cancer don't receive appropriate monitoring

December 1, 2015
An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance - closely monitoring their cancer - rather than aggressive treatment to avoid the debilitating potential side effects ...

Study suggests exercise benefit for localised prostate cancer

December 19, 2014
Moderate physical activity appears to reduce death rates among men diagnosed with prostate cancer that hasn't spread, according to a 15-year study by Swedish researchers

Prostate cancer surveillance criteria may not be accurate for African American men

January 4, 2016
A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) ...

Study finds prostate cancer tests underestimate disease in half of cases

April 11, 2014
A study published in the British Journal of Cancer suggests that tests to grade and stage prostate cancer underestimated the severity of the disease in half of men whose cancers had been classified as 'slow growing'.

Aspirin may decrease death from prostate cancer, study finds

January 5, 2016
(HealthDay)—Men who take aspirin regularly may have a lower risk of dying from prostate cancer, a new study suggests.

Research breakthrough could lead to better prostate cancer treatment

November 19, 2015
Cancer researchers from the University of Glasgow and Royal Philips Cancer researchers have identified a gene which could help doctors to predict the aggressiveness of prostate cancer in patients.

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.